Manchester Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Manchester Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1	Closed	-$145	–	1412
2025 Q3	$145	Hold	1	–	–	﹤0.01%	1270
2025 Q2	$127	Hold	1	–	–	﹤0.01%	1184
2025 Q1	$128	Hold	1	–	–	﹤0.01%	1150
2024 Q4	$133	Hold	1	–	–	﹤0.01%	1136
2024 Q3	$146	Hold	1	–	–	﹤0.01%	1151
2024 Q2	$138	Buy	+1	New	+$133	﹤0.01%	1127
2023 Q2	–	Sell	-75	Closed	-$9.69K	–	1049
2023 Q1	$9.69K	Hold	75	–	–	﹤0.01%	548
2022 Q4	$9.85K	Hold	75	–	–	﹤0.01%	468
2022 Q3	$9K	Hold	75	–	–	﹤0.01%	457
2022 Q2	$9K	Hold	75	–	–	﹤0.01%	495
2022 Q1	$10K	Hold	75	–	–	﹤0.01%	540
2021 Q4	$11K	Hold	75	–	–	﹤0.01%	555
2021 Q3	$12K	Hold	75	–	–	﹤0.01%	572
2021 Q2	$12K	Hold	75	–	–	﹤0.01%	486
2021 Q1	$11K	Sell	75 -70	-48%	-$11.1K	﹤0.01%	478
2020 Q4	$22K	Hold	145	–	–	﹤0.01%	420
2020 Q3	$20K	Hold	145	–	–	﹤0.01%	386
2020 Q2	$20K	Buy	+145	New	+$18.5K	﹤0.01%	428

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Manchester Capital Management's IBB Position: Q4 2025 in Review

Manchester Capital Management sold out of iShares Biotechnology ETF (IBB) in Q4 2025, closing a stake of 1 share — an estimated $145 sold.

Manchester Capital Management first reported a position in IBB in Q2 2020 and held it in 18 quarters. The position peaked at $22K in Q4 2020. 958 funds tracked by Wall St. Rank hold IBB as of Q4 2025.

Manchester Capital Management reported no remaining iShares Biotechnology ETF position as of Q4 2025 after selling out during the quarter.
Manchester Capital Management sold 1 iShares Biotechnology ETF share in Q4 2025, an estimated $145.
Manchester Capital Management first reported a position in iShares Biotechnology ETF in Q2 2020 and held it in 18 quarters.
Manchester Capital Management's iShares Biotechnology ETF position peaked at $22K in Q4 2020.
958 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2025.

Based on Manchester Capital Management's 13F filing for Q4 2025, filed 11 Feb 2026.